Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:01pm, Monday, 05'th Jan 2026
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m.
Stanley Laman Group Ltd. Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX
07:04am, Monday, 05'th Jan 2026
Stanley Laman Group Ltd. trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 40.4% during the third quarter, according to the company in its most recent 13F filing with the Securiti
Cwm LLC Has $11.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX
04:07am, Monday, 29'th Dec 2025
Cwm LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 218.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Excha
Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage
08:14am, Tuesday, 23'rd Dec 2025
Neurocrine Biosciences Inc. (NASDAQ: NBIX) on Monday shared data from its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants
Neurocrine's movement disorder treatment fails late-stage trial
04:50pm, Monday, 22'nd Dec 2025
Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
04:05pm, Monday, 22'nd Dec 2025
SAN DIEGO , Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbena
Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX
03:16am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. cut its stake in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 22.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Leslie Norwalk Sells 5,000 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
04:44am, Friday, 19'th Dec 2025
Neurocrine Biosciences, Inc. (NASDAQ: NBIX - Get Free Report) Director Leslie Norwalk sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, December 15th. The shares were sol
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript
07:09pm, Tuesday, 16'th Dec 2025
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
04:01pm, Tuesday, 16'th Dec 2025
Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities Reviewed Positive Data
Bayesian Capital Management LP Makes New Investment in Neurocrine Biosciences, Inc. $NBIX
04:32am, Friday, 12'th Dec 2025
Bayesian Capital Management LP bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) in the second quarter, according to the company in its most recent disclosure with the Securi
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by California Public Employees Retirement System
03:58am, Friday, 12'th Dec 2025
California Public Employees Retirement System raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 3.9% during the second quarter, according to the company in its most recent 1
Neurocrine Biosciences to Host R&D Day on December 16
04:01pm, Tuesday, 09'th Dec 2025
SAN DIEGO , Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00
Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level
08:00am, Friday, 05'th Dec 2025
Neurocrine Biosciences stock, part of the high-ranking biotech industry group, is trading back inside a buy zone.
Fisher Asset Management LLC Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX
04:40am, Thursday, 04'th Dec 2025
Fisher Asset Management LLC lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 8.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exc
